Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts

Exelixis (EXEL) PT Raised to $33 at Guggenheim Following 4Q

February 13, 2019 10:01 AM EST

Guggenheim analyst Michael Schmidt raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $31.00) while maintaining a Buy rating following the company's 4Q earnings report. EXEL reported 4Q18 revenue of $229M, 22% above Street consensus of $188M. Non-GAAP diluted EPS was 0.37, driven mostly by a... More

Exelixis (EXEL) PT Lowered to $31 at Oppenheimer

February 13, 2019 7:58 AM EST

Oppenheimer analyst Silvan Tuerkcan lowered the price target on Exelixis (NASDAQ: EXEL) to $31.00 (from $40.00) while maintaining a Outperform rating.

The analyst commented, "EXEL reported 4Q $176.2M revenue beating $170.0M consensus driven by Cabometyx sales of $171.6M vs $166M consensus. Cabometyx sales grew... More